| Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial | Journal of Clinical Oncology | 2010 | 424 |
| Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers | Journal of Clinical Oncology | 2010 | 336 |
| Nasopharyngeal carcinoma | Annals of Oncology | 2010 | 161 |
| miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion | Biochemical and Biophysical Research Communications | 2010 | 160 |
| Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest | Cell Death and Differentiation | 2010 | 159 |
| Squamous cell carcinoma of the head and neck: diffusion-weighted MR imaging for prediction and monitoring of treatment response | European Radiology | 2010 | 118 |
| Alisol B, a novel inhibitor of the sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis | Molecular Cancer Therapeutics | 2010 | 116 |
| EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients | Carcinogenesis | 2010 | 115 |
| Population-based differences in treatment outcome following anticancer drug therapies | Lancet Oncology, The | 2010 | 110 |
| Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer | International Journal of Cancer | 2010 | 102 |
| KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas | Cancer Research | 2010 | 101 |
| miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling | Journal of Biological Chemistry | 2010 | 92 |
| Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells | European Journal of Pharmacology | 2010 | 83 |
| High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy | International Journal of Cancer | 2010 | 71 |
| Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion | Oncogene | 2010 | 70 |
| WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma | Cancer Biology and Therapy | 2010 | 60 |
| Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma | BMC Cancer | 2010 | 58 |
| The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines | Investigational New Drugs | 2010 | 55 |
| 15-Lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer | Thorax | 2010 | 54 |
| Pseudolaric acids: isolation, bioactivity and synthetic studies | Natural Product Reports | 2010 | 52 |
| The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines | Investigational New Drugs | 2010 | 52 |
| RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo | Cancer Letters | 2010 | 49 |
| Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma | Proteomics | 2010 | 43 |
| PARP inhibition in BRCA-mutated breast and ovarian cancers | Lancet, The | 2010 | 38 |
| Identification of a novel 12p13.3 amplicon in nasopharyngeal carcinoma | Journal of Pathology | 2010 | 37 |
